Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
Public ClinicalTrials.gov record NCT03422536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study identification
- NCT ID
- NCT03422536
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of Arizona
- Other
- Enrollment
- 78 participants
Conditions and interventions
Conditions
- HNSCC
- Head and Neck Basaloid Carcinoma
- Head and Neck Cancer
- Oropharyngeal Cancer
- Recurrent Head and Neck Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Squamous Cell Carcinoma of Unknown Primary Origin
- Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
- Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Stage IV Oropharyngeal Squamous Cell Carcinoma
- Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma
- Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Stage IVA Oropharyngeal Squamous Cell Carcinoma
- Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma
- Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Stage IVB Oropharyngeal Squamous Cell Carcinoma
- Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma
- Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma
- Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions
- Cetuximab Biological
- Ficlatuzumab Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 4, 2017
- Primary completion
- Mar 28, 2022
- Completion
- Apr 4, 2022
- Last update posted
- Sep 3, 2024
2017 – 2022
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03422536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2024 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03422536 live on ClinicalTrials.gov.